

1 **Structural characterization of cocktail-like targeting polysaccharides**
2 **from *Ecklonia kurome* Okam and their anti-SARS-CoV-2 activities**
3 *invitro*

4 Shihai Zhang^{1,3#}, Rongjuan Pei^{4#}, Meixia Li^{1,3#}, Hao Sun⁴, Minbo Su^{2,3}, Yaqi Ding^{1,3}, Xia Chen^{1,3},
5 Zhenyun Du^{1,3}, Can Jin^{1,3}, Chunfan Huang^{1,3}, Yi Zang^{2,3}, Jia Li^{2,3}, Yechun Xu^{2,3*}, Xinwen Chen^{4*},
6 Bo Zhang^{4*}, Kan Ding^{1,3*}

7 ¹*Glycochemistry and Glycobiology Lab, Key Laboratory of Receptor Research, ²National Center*
8 *for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia*
9 *Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, P. R. of China*

10 ³*University of Chinese Academy of Science, No.19A Yuquan Road, Beijing 100049, P. R. China*

11 ⁴*State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science,*
12 *Chinese Academy of Sciences, Wuhan, 430071, China*

13
14 *Corresponding authors

15 Corresponding address: Glycochemistry and Glycobiology Lab, Shanghai Institute of
16 MateriaMedica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Pudong, Shanghai
17 201203, P.R. of China

18 Kan Ding, E-mail: dingkan@sim.ac.cn; Bo Zhang, Email: zhangbo@wh.iov.cn; Xinwen Chen,
19 Email: chenxw@wh.iov.cn; Yechun Xu, Email: yexu@sim.ac.cn

20
21 #These authors contributed equally to this work.

22
23 **Abstract**

24 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological
25 agent responsible for the worldwide coronavirus disease 2019 (COVID-19) outbreak.

26 Investigation has confirmed that polysaccharide heparan sulfate can bind to the spike
27 protein and block SARS-CoV-2 infection. Theoretically, similar structure of nature
28 polysaccharides may also have the impact on the virus. Indeed, some marine
29 polysaccharide has been reported to inhibit SARS-Cov-2 infection *in vitro*, however
30 the convinced targets and mechanism are still vague. By high throughput screening to
31 target 3CLpro enzyme, a key enzyme that plays a pivotal role in the viral replication
32 and transcription using nature polysaccharides library, we discover the mixture
33 polysaccharide 375 from seaweed *Ecklonia kurome* Okam completely block 3CLpro
34 enzymatic activity (IC_{50} , 0.48 μ M). Further, the homogeneous polysaccharide 37502
35 from the 375 may bind to 3CLpro molecule well (kD value: 4.23×10^{-6}). Very
36 interestingly, 37502 also can potently disturb spike protein binding to ACE2 receptor
37 (EC_{50} , 2.01 μ M). Importantly, polysaccharide 375 shows good anti-SARS-CoV-2
38 infection activity in cell culture with EC_{50} values of 27 nM (99.9% inhibiting rate at
39 the concentration of 20 μ g/mL), low toxicity (LD_{50} : 136 mg/Kg on mice). By DEAE
40 ion-exchange chromatography, 37501, 37502 and 37503 polysaccharides are purified
41 from native 375. Bioactivity test show that 37501 and 37503 may impede
42 SARS-Cov-2 infection and virus replication, however their individual impact on the
43 virus is significantly less that of 375. Surprisingly, polysaccharide 37502 has no
44 inhibition effect on SARS-Cov-2. The structure study based on monosaccharide
45 composition, methylation, NMR spectrum analysis suggest that 375 contains
46 guluronic acid, mannuronic acid, mannose, rhamnose, glucouronic acid, galacturonic
47 acid, glucose, galactose, xylose and fucose with ratio of 1.86 : 9.56 : 6.81 : 1.69 :

48 1.00 : 1.75 : 1.19 : 11.06 : 4.31 : 23.06. However, polysaccharide 37502 is an aginate
49 which composed of mannuronic acid (89.3 %) and guluronic acid (10.7 %), with the
50 molecular weight (M_w) of 27.9 kDa. These results imply that mixture polysaccharides
51 375 works better than the individual polysaccharide on SARS-Cov-2 may be the
52 cocktail-like polysaccharide synergistic function through targeting multiple key
53 molecules implicated in the virus infection and replication. The results also suggest
54 that 375 may be a potential drug candidate against SARS-CoV-2.

55 **Keywords:**

56 *COVID-19; SARS-CoV-2; 3CL protease; angiotensin converting enzyme 2 (ACE2);*
57 *spike protein, Ecklonia kurome; Polysaccharide;*

58

59 **Introduction**

60 The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has
61 made a pandemic of Coronavirus Disease 2019 (COVID-19) cross the globe. Up to
62 now, this virus has spread more than 200 countries. Around 22 million confirmed
63 infection and 1500,000 have died in the past 6 months and the number is increasing
64 (Dong, Du, & Gardner, 2020). Keeping social distancing is a functional strategy to
65 slow down the infection due to the absence of vaccine or during the coming vaccine
66 injection period and effective medicine. Currently, only one anti-SARS-Cov-2 agent,
67 remdesivir, has been approved by FDA for the treatment of adult COVID-19 patients
68 (Beigel et al., 2020). Scientific research institutions and pharmaceutical companies
69 are trying to understand the mechanism of SARS-CoV-2 infection and potential

70 antiviral drug to treat COVID-19. A chymotrypsin-like cysteine protease called
71 3C-like protease (3CLpro) and papain-like protease (PLpro) are required to process
72 polyproteins into mature nonstructural proteins such as RNA-dependent RNA
73 polymerase (RdRp) and helicase, which are essential for viral transcription and
74 replication (Su et al., 2020). Shailendra K. Saxena, et al, found that SARS-CoV-2 had
75 only 12.8 % of difference with SARS-CoV in S protein and has 83.9 % similarity in
76 minimal receptor-binding domain with SARS-CoV (Kumar, Maurya, Prasad, Bhatt, &
77 Saxena, 2020). In 2003, it had been identified that angiotensin-converting enzyme 2
78 (ACE2) could efficiently bind to the S1 domain of the SARS-CoV S protein (Li et al.,
79 2003). The S protein is a heavily glycosylated protein, which possess 22 potential
80 N-glycosylation sites and facilitates attachment, entry and membrane fusion
81 (Shajahan, Supekar, Gleinich, & Azadi, 2020). Previous researchers showed that
82 several viruses interacted with sialic acids located on the ends of glycans in
83 glycolipids and glycoproteins surrounding the cells. Some other viruses might interact
84 with heparan sulfate (HS) that is attached to cell membrane (Milewska et al., 2014) or
85 extracellular matrix proteoglycans (Lindahl, Couchman, Kimata, & Esko, 2015).

86 Latest research found that SARS-CoV-2 entry the human cell through binding of
87 the virus spike (S) protein to angiotensin-converting enzyme 2 (ACE2) and cellular
88 HS on the surface of the host cell (Clausen et al., 2020). Hence, blocking the viral
89 transcription, replication and interfering the binding of SARS-CoV-2 and human cells
90 targeting the glycan on ACE2 or spike (S) protein are rational strategies to fight
91 SARS-Cov-2 infection. Interestingly, traditional Chinese medicine has been paid

92 more attention for antiviral clinical drug application during SARS-CoV and
93 SARS-CoV-2 spreading (Leung, 2007; H. Luo et al., 2020; Wen et al., 2011). Indeed,
94 Baicalin and baicalein, two ingredients of Chinese traditional patent medicine
95 Shuanghuanglian, were characterized as the first noncovalent, nonpeptidomimetic
96 inhibitors of SARS-COV-2 3CLpro and exhibited potent antiviral activities in a
97 cell-based system (Su et al., 2020) . However, the detailed mechanism underlying
98 active components against the virus is still vague.

99 Traditional Chinese medicine *Ecklonia kurome*, named Kunbu in China, is a
100 seaweed of the *Laminariaceae*, belonging to the genus *Laminariales* (Kuda, Kunii,
101 Goto, Suzuki, & Yano, 2007). The high pharmaceutical value of this seaweed is at
102 least partially relied on the biomacromolecule polysaccharide. Different from other
103 general polysaccharide, the polysaccharide in *Ecklonia kurome* is mainly present on
104 cell wall of brown algae plants and has a sulfate group at the end of its molecular
105 chain, which may make it have significance bio-activities (Li et al., 2020). For
106 instance, a modified sulfate polysaccharide extracted from *Ecklonia kurome* has
107 anti-angiogenesis anti-tumor effect (Kuda et al., 2007). Alginate, a mainly acid
108 polysaccharide in *Ecklonia kurome*, is a linear anionic polymer of
109 β -(1-4)-D-mannuronic acid and of its C-5 epimer, α -(1-4)-L-guluronic acid. They
110 consist of alternate homopolymeric blocks of poly- β -(1-4)-D-mannuronic acid (M),
111 and poly- α -(1-4)-L-guluronic acid (G), and of heteropolymeric blocks with random
112 arrangements of both monomers (Fujihara & Nagumo, 1993). Previous research
113 revealed that alginate had the effect on anti-tumor and immunoenhancement (de

114 Sousa et al., 2007; Luo, Wu, Lou, Zhao, & Yang, 2020), however no anti-virus effect
115 was reported.

116 In this study, we firstly extracted crude polysaccharide, named 375 from
117 *Ecklonia kurome* and examine the bioactivity against SARS-Cov-2 virus. Then we
118 isolated and purified crude polysaccharide and further characterized the structure of
119 one homogeneous polysaccharide 37502 from *Ecklonia kurome*. The molecular
120 weight (M_w), monosaccharide composition, infrared spectroscopy (IR) and nuclear
121 magnetic resonance (NMR) spectra were employed to analyze the structure.
122 Eventually, we further examined anti-SARS-CoV-2 bioactivity by targeting 3CL pro,
123 S1 and ACE2 molecules.


124

125 **Results and discussion**

126 **Isolation, purification and monosaccharide composition analysis of 37502**

127 The crude polysaccharide, 375 (200 mg) was fractioned by DEAE Sepharose™
128 Fast Flow. 37501 (20 mg, yield: 10 %), 37502 (44 mg, yield: 22 %) and 37503 (35 mg,
129 yield: 17 %) were obtained by elution with distilled water, 0.2 M NaCl and 0.3 M
130 NaCl (**Fig. 1**). 375 content 65 % neutral polysaccharide, 5 % protein and 28 % uronic
131 acid. 37501 content 12 % neutral polysaccharide and 7.7 % uronic acid. 37502
132 content 16.4 % neutral polysaccharide and 32.0 % uronic acid. The sugar content,
133 protein and uronic acid of 37503 were 40.3 %, 2.3 % and 11.9 %, respectively. The
134 homogeneity of 37502 was determined by high performance gel
135 permeation chromatography (HPGPC) that showed a single symmetrical peak with

136 the M_w of 27.9 kDa (**Fig. S1A, Supplementary data**). The monosaccharide
137 compositions of 375, 37501, 37502 and 37503 were analyzed by HPLC after PMP
138 derivatization with PMP in parallel with monosaccharides standards. Compared with
139 standards, the monosaccharide composition of 375, 37501 and 37503 were shown in
140 **Fig. S2**, the crude polysaccharide 375 contained guluronic acid (3.0 %), mannuronic
141 acid (15.3 %), mannose (10.9 %), rhamnose (2.7 %), glucouronic acid (1.6 %),
142 galacturonic acid (2.8 %), glucose (1.9 %), galactose (17.7 %), xylose (6.9 %) and
143 fucose (36.9 %). 37501 mainly contained guluronic acid (1.4 %), mannuronic acid
144 (3.6 %), mannose (14.6 %), rhamnose (3.6 %), glucouronic acid (2.0 %), galactose
145 (28.1 %), xylose (7.37 %) and fucose (39.1 %). 37503 was composed of mannose
146 (30.1 %), rhamnose (9.6 %), glucose (3.4 %) galactose (7.3 %), xylose (10.9 %) and
147 fucose (36.9 %). Relatively, the monosaccharide composition of 37502 was more
148 simple, it was composed of mannuronic acid (89.3 %) and guluronic acid (10.7 %) as
149 shown in (**Fig. 2**). More structure information was revealed by FT-IR and NMR
150 spectra.



151
152 Fig. 1. Elution profile of 375 on DEAE Sepharose Fast Flow with different NaCl; a. distilled
153 water elution profile; b. 0.2 M NaCl elution profile; c. 0.3 M NaCl elution profile.
154 concentration.




Fig. 2

155

156 Fig. 2. Determination of monosaccharide composition of 37502 by HPLC. A. 37502; B.

157 Monosaccharide standards (1. guluronic acid; 2. mannuronic acid; 3. Mannose; 4. Rhamnose;

158 5. Glucouronic acid; 6. Glactouronic acid; 7. Glucose; 8. Galactose; 9. Xylose; 10. Arabinose;

159 11. Fucose).


160 FT-IR spectrum

161 FT-IR spectrum of 37502 showed the typical absorption bands of the
162 polysaccharide (**Fig. 3**). 3453.88 cm^{-1} was assigned to the O-H stretching bands.

163 2935.13 cm^{-1} was from the stretching bands of C-H group. 1616.06 cm^{-1} and 1417.42

164 cm^{-1} could be reassigned to the asymmetrical and symmetrical stretching vibration

165 of COO⁻, respectively, which confirmed the presence of uronic acid. The absorption at
166 1035.59 cm⁻¹ showed the existence of the stretching vibration of C-C. 956.52 cm⁻¹ was
167 the stretching vibration of uronic acid residues. 890.95 cm⁻¹ was the variable angular
168 vibration of C1-H of β-mannuronic acid (Mao, Li, Gu, Fang, & Xing, 2004). 821.53
169 cm⁻¹ was the special absorption peak of mannuronic acid and 792.12 cm⁻¹ was the
170 special absorption peak of guluronic acid (Lin et al., 2007).



171 **Fig. 3**


172 Fig. 3. FT-IR spectrum of 37502

173 **Linkage pattern analysis**

174 In order to determine the linkage types, the methylation method was employed.
175 First, 37502 was reduced with 1-Cyclo-hexyl-3-(2-mopholinoethyl)
176 carbodiimidemetho-p-toluenesulfonate (CMC) and the reduced production was
177 further methylated. Result revealed that there are mainly 2,3,6-Me₃-Man and little 2, 3,
178 4, 6-Me₄-Man, indicating that 37502 was a linear 1, 4-linked mannosan. More
179 structure information will be shown by NMR spectra.

180 **NMR spectral analysis**

181 ^{13}C NMR spectra of 375, 37502 and 37503 were compared in **Fig. S3** and the ^1H ,
182 ^{13}C NMR spectra of 37502 were shown in **Fig. 4**. In the ^{13}C NMR spectra of 37502
183 (**Fig. 4A**), the signals at δ 102.45 ppm and 101.22 ppm were assigned to C1 of 1,
184 4-linked α -L-galuronic acid and 1, 4-linked β -D-mannuronic acid, respectively
185 (Heyraud et al., 1996). The strong signals at δ 65.87, δ 78.46 and δ 68.57 were
186 ascribed to C-2, C-3 and C-5 of the 1,4-linked α -L-galuronic acid. The signals at δ
187 71.12, δ 72.55 and δ 76.69 were ascribed to C-2, C-3 and C-5 of the 1, 4-linked
188 β -D-mannuronic acid. The signals at δ 81.2 and δ 79.06 were assigned to C-4 of
189 1,4-linked α -L-galuronic acid and 1, 4-linked β -D-mannuronic acid, respectively
190 (Schürks, Wingender, Flemming, & Mayer, 2002).



191 **Fig. 4**

191

192

Fig. 4. ^1H NMR spectrum (A) and ^{13}C NMR spectrum (B) of 37502.

193

In the ^1H NMR (**Fig. 4B**) and HSQC (**Fig. 5B**) spectra, δ 5.12 was assigned to H-1

194 of 1,4-linked α -L-guluronic acid, which correlated to C-1 of 1,4-linked α -L-guluronic
195 acid (102.45 ppm). δ 4.73 was assigned to H-1 of 1, 4-linked β -D-mannuronic acid
196 correlated to C-1 of 1, 4-linked β -D-mannuronic acid (101.22 ppm). In ^1H - ^1H COSY
197 (**Fig. 5A**) spectra, δ 4.04 was assigned to H-2 of 1,4-linked α -L-guluronic acid, which
198 correlated to H-1 (δ 5.12) of 1,4-linked α -L-guluronic acid. δ 4.10 was assigned to
199 H-2 of 1, 4-linked β -D-mannuronic acid, which correlated to H-1 (δ 4.73) of 1,
200 4-linked β -D-mannuronic acid. Other signals were listed in **Table.1**.

201 Table.1. ^1H NMR and ^{13}C NMR chemical shifts (ppm) assignments for 37502.

| Residues | | 1 | 2 | 3 | 4 | 5 | 6 |
|---------------------------------|---|--------|-------|-------|-------|-------|--------|
| 1, 4-linked guluronic acid (G) | C | 102.45 | 65.87 | 78.46 | 81.2 | 68.57 | 176.58 |
| | H | 5.12 | 4.04 | 3.95 | 4.29 | 4.53 | |
| 1, 4-linked mannuronic acid (M) | C | 101.22 | 71.12 | 72.55 | 79.06 | 76.69 | 175.96 |
| | H | 4.73 | 4.10 | 3.83 | 3.93 | 3.87 | |

202 HMBC spectrum was employed to analyze the structure backbone and the
203 substitution sites. In **Fig. 5C**, the strong peak 1 (101.22/3.93) represented the
204 correlation between C-1 and H-4 of 1, 4-linked mannuronic acid. The cross peak 2
205 (79.06/4.73) represented the correlation between C-4 and H-1 of 1, 4-linked
206 mannuronic acid. These two peaks showed the existence of liner 1, 4-linked
207 mannuronic acid. The cross peak 3 (101.22/4.29) showed the correlation between C-1
208 of 1, 4-linked mannuronic acid and H-4 of the neighboring 1, 4-linked guluronic acid.
209 The peak 4 (81.2/4.73) represent the correlation between C-4 of 1, 4-linked guluronic
210 acid and H-1 of the neighboring 1, 4-linked mannuronic acid. These results suggested
211 that guluronic acid may linked to the liner mannuronic acid. The cross peak 5
212 (102.45/4.29) showed the correlation between C-1 of 1, 4-linked guluronic acid and

213 H-4 of neighboring 1, 4-linked guluronic acid, which showed the existence of liner 1,
214 4-linked guluronic acid. The cross peak 6 (102.45/3.93) overlapped by peak 1 showed
215 the correlation between C-1 of 1, 4-linked guluronic acid and H-4 of neighboring 1,
216 4-linked mannuronic acid. The cross peak 7 (79.06/5.12) also showed the correlation
217 between C-4 of 1, 4-linked mannuronic acid and H-1 of 1, 4-linked guluronic acid. It
218 showed the existence of heteropolymeric blocks with random arrangements of both
219 mannuronic acid and guluronic acid.





Fig. 5

221 Fig. 5. Two dimensional spectra of 37502; A. 1H-1H COSY spectrum; B. HSQC spectrum;
222 C. HMBC of spectrum.

223 Putative structure of 37502

224 Based on the above results, we proposed that 37502 is an alginate consisting of
225 different dimer structures (MM, MG, GM and GG). The molar ratio (F) of dimer
226 structures was speculated according to the integral area (I) of **a**, **b**, **c** in ¹H-NMR and
227 following formula: $F_G = Ia/(Ib+Ic)$, $F_{GG} = Ic/(Ib+Ic)$, $F_{GG} + F_{GM} = F_G$, $F_{MM} + F_{MG} = F_M$,
228 $F_{MG} = F_{GM}$. In ¹H-NMR of 37502, the integral area of **a**, **b**, **c** was 1.0, 4.85 and 0.55,
229 respectively. So, $F_G = 0.19$; $F_M = 0.9$; $F_{MM} = 0.81$; $F_{GG} = 0.1$; $F_{GM} = F_{MG} = 0.09$. The
230 molar ratio (0.19: 0.9) of between F_G and F_M was consisted of the results of
231 monosaccharide composition. The ratio of F_{MM} was highest and the ratio of F_{GG} , F_{MG}
232 and F_{GM} was similar. Finally, the possible structure of 37502 (M_w : 27.9 kDa) was
233 shown in **Fig. 6**.



234 Fig. 6

235 Fig. 6. Proposed structure of 37502

236 Crude polysaccharide 375 was a potent inhibitor of SARS-COV-2 3CLpro

237 People showed that marine polysaccharide may inhibit SARS-Cov-2 infection (Song
238 S, et al. 2020), however the convinced targeting molecule and mechanism are still
239 unknown. SARS-CoV-2 includes two open reading frames ORF1a and ORF1b (Yin et

240 al., 2020). ORF1a encodes two cysteine proteases, a papain-like protease (PLpro) and
241 a 3 C-like protease (3CLpro). Scientists have provided evidences that main protease
242 (3CLpro) is one of the good targets to discover new antiviral agents before vaccines
243 are available (Derosa, Maffioli, D'Angelo, & Di Pierro, 2020). To explore more potent
244 leading compound against SARS-Cov-2 by targeting key molecule in RNA synthesis
245 of the virus, recombinant SARS-CoV-2 3CLpro was firstly expressed and purified
246 from *Escherichia coli* (Xue et al., 2007; Yang et al., 2003). A fluorescently labeled
247 substrate MCA-AVLQSGFR-Lys (Dnp) -Lys-NH₂, derived from the N-terminal
248 autocleavage sequence from the viral protease was designed and synthesized for the
249 enzymatic assay. Then the binding test targeting 3CLpro was examined. The results
250 showed that 375 might potently inhibit SARS-CoV-2 3CLpro activity (Fig. 7). Further
251 we used a fluorescence resonance energy transfer (FRET) based cleavage assay to
252 determine the median inhibitory concentration (IC₅₀) values. The results also revealed
253 good inhibitory potency, with IC₅₀ values of $0.48 \pm 0.1 \mu\text{M}$ (Fig. 7). It implies that
254 375 may contain the bioactive components to inhibit SARS-CoV-2 replication and
255 infection. Based on fact that 375 is a crude polysaccharide, the results inspire us to
256 explore which bioactive components from crude polysaccharide 375 may contribute
257 the effect against SARS-Cov-2 and their underlying mechanism.




Fig. 7

258


259 Fig. 7. Inhibitory activity profiles of 375 against SARS-CoV-2 3CLpro

260 **37502 may bind to SARS-CoV-2 3CLpro and disturb the interaction between**
261 **SARS-CoV-2-S1 and ACE2**

262 To explore which compound from 375 may interfere with 3CLpro enzyme activity,
263 isothermal titration calorimetry (ITC) method was employed (Su et al., 2020). Result
264 showed that. 37502, one homogeneous polysaccharide from 375 could bind to
265 SARS-CoV-2 3CLpro protein very well (Fig. 8A). The K_d value was 4.23×10^{-6} M
266 (Fig. 8A). This result suggested that 375 or 37502 might interfere with the replication
267 of SARS-CoV-2 in some way.

268 The spike protein of SARS-CoV-2 shows more than 90% amino acid similarity to
269 that of pangolin and bat CoVs which also use human angiotensin-convert enzyme 2
270 (ACE2) as a receptor for the virus infection. Receptor binding domain of S protein of
271 SARS-CoV-2 which are processed into two subunits including S1 and S2, can bind
272 with ACE2 as a receptor to invade target cells (Lan et al., 2020). Thus, S protein is
273 very vital for viral invasion. Interestingly, the N-terminal domain of S1 protein has the
274 glycan binding site (Kirchdoerfer et al., 2016). This implies S protein can bind with

275 carbohydrate. To further understand the bioactivity of 375 against SARS-Cov-2,
276 purified homogeneous polysaccharide 37502 from 375 was employed to examine
277 whether it might disturb the binding between S1 protein and ACE2 by ELISA method.
278 The results showed that polysaccharide 37502 could effectively impede the binding of
279 S1 protein with ACE2. The median inhibitory concentration (IC_{50}) was 56.06 $\mu\text{g}/\text{mL}$
280 (**Fig. 8B**). This result suggested that 37502 might had the potential to block
281 SARS-Cov-2 infection through disturbing the S protein binding to ACE2 receptor.



282 **Fig. 8**

283
284 Fig. 8. (A) Binding test of polysaccharide 37502 with SARS-CoV-2 3CLpro by ITC.
285 (B) Competitive intervention of polysaccharide 37502 on S1 protein and ACE2 by
286 ELISA.

287 **375 and 37503 exhibit anti-viral effect on SARS-CoV-2**

288 The above results inspired us to explore whether those polysaccharides might really
289 block SARS-Cov-2 replication. Firstly, the inhibition effect of native polysaccharide
290 375 was examined. Surprisingly, as shown in **Fig. 9A**, polysaccharides 375 potently
291 inhibit SARS-Cov-2 *in vitro* with a EC_{50} value about 27 nM (or 1.56 $\mu\text{g}/\text{mL}$) (**Fig.**

292 **9A)**. However, the toxicity of 375 on mice is low and the LD₅₀ is 136 mg/kg (**Table**
293 **S1, Supplementary Data**). To further understand which component from native
294 polysaccharide 375 is contributing to inhibit effect on SARS-Cov-2, quantitative
295 real-time polymerase chain reaction (qRT-PCR) was also employed to monitor the
296 antiviral activity of the purified polysaccharide 37501, 37502 and 37503 from 375.
297 The result showed that polysaccharide 37501 and 37503 exhibited antiviral effect on
298 SARS-CoV-2 (**Fig. 9B**). Although 37502 might attenuate 3CLpro enzymatic activity
299 significantly (**Fig. 8A**), it had no significant direct effect against the active virus
300 replication (**Fig. 9B**). To examine whether purified polysaccharide 37503 have
301 stronger bioactivity than that of native polysaccharide 375, EC₅₀ of 37503 against
302 SARS-Cov-2 was also measured. Interestingly, effect of 37503 is significant feeble
303 than that of 375, while EC₅₀ of 37503 is 0.89 μM (or 11.07 μg/mL) (**Fig. 9C**). This
304 indicated the effects of 375 against SARS-Cov-2 were cocktail-like synergistic
305 contribution of combined components of 37501, 37502, and 37503, the impact of
306 individual homogeneous polysaccharide might be weaker although. In brief, although
307 polysaccharide 375 and 37503 are probably the potential drug candidate for inhibiting
308 the SARS-CoV-2 infection, obviously cocktail-liked crude polysaccharide 375 is the
309 best option for anti-SARS-Cov-2 new drug development. Following, we will focus on
310 375 and 37503 for further investigation.




Fig. 9

311

312 Fig. 9. *In vitro* inhibition of polysaccharides against SARS-CoV-2. (A) EC₅₀ of crude
313 polysaccharide 375 against SARS-CoV-2; (B) viral RNA copy number was detected by qPCR
314 after the treatment of solvent (H₂O) control, Remdesivir positive control, crude
315 polysaccharide 375 and their fragmentation 37501, 37502 and 37503. (C) EC₅₀ of
316 homogenous polysaccharide 37503 against of SARS-CoV-2.

317 Experimental

318 Materials and reagents

319 DEAE Sepharose Fast Flow was obtained from GE healthcare. Dimethyl
320 sulfoxide (DMSO) was from E. Merck. U.S.A. Sodium borohydride (NaBH₄) and
321 iodomethane were obtained from Sinopharm Chemical Reagent Co. Ltd. Standard
322 monosaccharides were purchased from Shanghai Aladdin Bio-Chem Technology Co.
323 Ltd. Other reagents were analytical grade and from Sinopharm Chemical Reagent Co.
324 Ltd. (Shanghai, China).

325 Determination of physicochemical property of polysaccharides

326 The carbohydrate content was determined by the PhOH-H₂SO₄ method using
327 glucose as a standard (Dubios, Gilles, Hamilton, Rebers, & Smith, 1956). Protein
328 content was evaluated using a BCA protein assay kit (Beyotime Biotechnology,
329 China). Uronic acid content was determined by the meta-hydroxydiphenyl method

330 using galacturonic acid as a standard. All the measurements were repeated three times.
331 Novostar microplate reader was employed to detect the absorbance at OD₄₉₀ for sugar,
332 OD₅₂₀ for uronic acid and OD₅₆₂ for protein.

333 **Homogeneous polysaccharide preparation**

334 Crude polysaccharide was fractionated on a DEAE Sepharose Fast Flow column.
335 200 mg polysaccharide was dissolved in 20 mL distilled water and centrifuged for
336 each time. The supernatant was applied to a DEAE Sepharose Fast Flow column and
337 eluted with distilled water, 0.05, 0.1, 0.2 and 0.3 M NaCl solutions stepwise. The
338 solution was pooled according to the elution profile based on phenol-sulfuric acid
339 method. Then the fraction eluted with distilled water, 0.2 M NaCl and 0.3 M NaCl
340 were collected, followed by concentration, dialysis with distill water and freeze-dried.

341 **Homogeneity and molecular weight**

342 The homogeneity and molecular weight (M_w) were examined by HPGPC (high
343 performance gel permeation chromatography) method on Agilent 1260 HPLC (Santa
344 Clara, CA, USA) system equipped with two series-connected columns
345 (Ultrasphere™ 2000 and 500). The columns were calibrated by pullulans standards.
346 0.1 mol/L NaNO₃ was used as an eluent and the flow rate was maintained at 0.6
347 mL/min. The column temperature was maintained at 40.0 °C ± 0.1 °C. The samples
348 were prepared with mobile phase as 0.2 % (W/V) solution. 20 µL of sample was
349 injected for analysis.

350 **Monosaccharide composition analysis**

351 The method of monosaccharide composition was PMP pre-column derivatisation

352 based on the previous reported (Dai et al., 2010).

353 **FT-IR spectrum and NMR analysis**

354 The IR spectra was determined according to the previous report (Cong, Xiao,
355 Liao, Dong, & Ding, 2014). 2 mg native polysaccharide was mixed with dried KBr
356 powder and pressed into pellet, then scanned from 4,000 to 600 cm^{-1} for the analysis.

357 For the NMR analysis, 30 mg of the sample was deuterium-exchanged and
358 dissolved in 0.5 mL D_2O . The ^1H NMR, ^{13}C NMR, ^1H - ^1H COSY, HSQC and HMBC
359 were measured at 25 °C with acetone as internal standard ($\delta_{\text{C}} = 31.5$, $\delta_{\text{H}} = 2.29$). NMR
360 spectra were recorded on a Bruker AVANCE III NMR spectrometer operating at 500
361 MHz.

362 **Methylation analysis**

363 10 mg sample was methylated with a modified method from Ciucanu and Kerek.
364 Briefly, the sample was dried overnight with P_2O_5 and dissolved in DMSO (2 mL) and
365 100 mg powdered NaOH was added into the reaction bulb and stirred at room
366 temperature for 3 h. Iodomethane (0.5 mL) was added dropwise within 45 min in
367 ice-cold water bath. The mixture was stirred for 2.5 h at room temperature in a dark
368 place and then 1 ml deionized water was added to terminate the reaction. The
369 redundant CH_3I was removed by evaporation under depressed pressure. The solution
370 was extracted by 15 ml CHCl_3 and 15 ml water (1:1, v/v) and the organic phase was
371 washed with deionized water for three times. After removing the residual water by
372 adding Na_2SO_4 , the organic phase was concentrated to get the methylated
373 polysaccharide. Then the product was hydrolyzed with 2 M TFA for 2 h at 110 °C and

374 converted into the partially methylated alditol acetates (PMAA) and analyzed by
375 GC-MS. The GC-MS program designed for methylation analysis was based on the
376 reported method (Cong et al., 2014).

377 **Uronic acid reduction**

378 The method was based on the reported method (Taylor & Conrad, 1972). In brief,
379 40 mg polysaccharide was dissolved in 40 mL H₂O. CMC (600 mg) was added and
380 pH was kept at 4.75 with 0.01 M HCl for 2 h. Then 2 M fresh aqueous sodium
381 borohydride (15 mL) was added slowly to the mixture in 45 min and 4 M HCl was
382 added concurrently to keep pH at 7.0. The mixture was stirred for 2 h and dialyzed
383 (1,000 mL × 4) for 24 h at room temperature. Then the retentate was lyophilized to
384 achieve carboxyl reduced polysaccharide, followed by monosaccharide composition
385 and linkage pattern analyses.

386 **Enzymatic activity and inhibition assays**

387 The enzyme activity and inhibition assays have been described previously (Xue
388 et al., 2007; Yang et al., 2005) . The recombinant SARS-CoV-2 3CLpro (30 nM at a
389 final concentration) was mixed with serial dilutions of each compound in 80 µL assay
390 buffer (50 mM Tris-HCl, pH 7.3, 1 mM EDTA) and incubated for 10 min. The
391 reaction was initiated by adding 40 µL fluorogenic substrate with a final concentration
392 of 20 µM. After that, the fluorescence signal at 320 nm (excitation)/405 nm (emission)
393 was immediately measured every 30 s for 10 min with a Bio-Tek Synergy4 plate
394 reader. The V_{max} of reactions added with compounds at various concentrations
395 compared to the reaction added with DMSO were calculated and used to generate IC₅₀

396 curves. For polysaccharide 375, IC_{50} values against SARS-CoV-2 3CLpro were
397 measured at 7 concentrations and three independent experiments were performed. All
398 experimental data was analyzed using GraphPad Prism software.

399 **ELISA**

400 10 μ g/mL ACE2 coating buffer were used to treat the 96 well plate at 4 °C
401 overnight following with 200 μ L washing buffer for three times. Then the 96-well
402 plate was blocked by 2% BSA at room temperature for 2 h. After that, 100 μ L
403 biotinylated S1 protein was added and incubated at room temperature. At the same
404 time, the positive control and the negative control were set. After incubation for 1 h,
405 the plate was washing for three times and each time for 5 min. Following, 100 μ L
406 Streptavidin-HRP was added to final concentration of 200 ng/mL at room temperature
407 and incubated for 1 h. After 1 h incubation, the plate was washed for three times.
408 Then, 100 μ L TMB were added and incubated in the dark for 35 min. Finally, 50 μ L
409 stop solution were added to stop the reaction and detected the A450 value number by
410 microplate reader (BioTek).

411 **Isothermal Titration Calorimetry (ITC)**

412 ITC experiment was performed as previously publication (Su et al., 2018). It was
413 conducted with an iTC200 instrument (Microcal, GE Healthcare) at 25 °C, and the
414 resulting data were processed by the supplied MicroCal Origin software package. The
415 concentration of 3CLpro protein used was 600 μ M and polysaccharide 37502 used
416 was 300 μ M. Titrations were run in triplicate to ensure reproducibility. In all the cases,
417 a single binding site mode was employed and a nonlinear least-squares algorithm was

418 used to obtain best-fit values of the stoichiometry (n), change in enthalpy (ΔH), and
419 binding constant (K). Thermodynamic parameters were subsequently calculated with
420 the formula $\Delta G = \Delta H - T \Delta S = -RT \ln K$, where T , R , ΔG , and ΔS are the
421 experimental temperature, the gas constant, the changes in free energy, and entropy of
422 binding, respectively.

423 **Antiviral test *in vitro***

424 The experiments related to SARS-CoV-2 are completed at biosafety level 3
425 (BSL-3) laboratory in the Center for Biosafety Mega-Science, Wuhan, Chinese
426 Academy of Sciences.

427 SARS-CoV-2 (WIV04) was passaged in Vero E6 cells and tittered by plaque
428 assay. Vero E6 cells were treated with drugs at indicated concentration and infected by
429 SARS-CoV-2 virus at MOI 0.01. After 24 h incubation at 37 °C, supernatants were
430 collected and the viral RNAs were extracted by Magnetic Beads Virus RNA
431 Extraction Kit (Shanghai Finegene Biotech, FG438), and quantified by real-time
432 RT-PCR with Taqman probe targeting to the RBD region of S gene.

433

434 **Acknowledgment**

435 This work was supported by Key New Drug Creation and Manufacturing Program
436 (Grant number 2019ZX09735001), National Key R&D Program of China, Ministry of
437 Science and Technology (Grant number 2019YFC1711-000). COVID-19 Emergency
438 Research Project founded by Zhejiang University (2020XGZX080). We are
439 particularly grateful to Tao Du and Lun Wang from the Center for Biosafety

440 Mega-Science for their essential support.

441 References

- 442 Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., et al. (2020).
443 Remdesivir for the treatment of Covid-19 - final report. *The New England Journal of*
444 *Medicine*, 383(19), 1813-1826. doi:[10.1056/NEJMoa2007764](https://doi.org/10.1056/NEJMoa2007764)
- 445 Clausen, T. M., Sandoval, D. R., Spliid, C. B., Pihl, J., Perrett, H. R., Painter, C. D., et al. (2020).
446 SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2. *Cell*, 183(4),
447 1043-1057.e1015. doi:[10.1016/j.cell.2020.09.033](https://doi.org/10.1016/j.cell.2020.09.033)
- 448 Cong, Q., Xiao, F., Liao, W., Dong, Q., & Ding, K. (2014). Structure and biological activities of an
449 alginate from *Sargassum fusiforme*, and its sulfated derivative. *International Journal of*
450 *Biological Macromolecules*, 69, 252-259. doi:<https://doi.org/10.1016/j.ijbiomac.2014.05.056>
- 451 Dai, J., Wu, Y., Chen, S.-w., Zhu, S., Yin, H.-p., Wang, M., & Tang, J. (2010). Sugar compositional
452 determination of polysaccharides from *Dunaliella salina* by modified RP-HPLC method of
453 precolumn derivatization with 1-phenyl-3-methyl-5-pyrazolone. *Carbohydrate Polymers*,
454 82(3), 629-635. doi:<https://doi.org/10.1016/j.carbpol.2010.05.029>
- 455 De Sousa, A. P. A., Torres, M. R., Pessoa, C., Moraes, M. O. d., Filho, F. D. R., Alves, A. P. N. N., &
456 Costa-Lotufo, L. V. (2007). In vivo growth-inhibition of Sarcoma 180 tumor by alginates from
457 brown seaweed *Sargassum vulgare*. *Carbohydrate Polymers*, 69(1), 7-13.
458 doi:<https://doi.org/10.1016/j.carbpol.2006.08.018>
- 459 Derosa, G., Maffioli, P., D'Angelo, A., & Di Pierro, F. (2020). A role for quercetin in coronavirus
460 disease 2019 (COVID-19). *Phytotherapy Research*, n/a(n/a).
461 doi:<https://doi.org/10.1002/ptr.6887>
- 462 Dong, E., Du, H., & Gardner, L. (2020). An interactive web-based dashboard to track COVID-19 in
463 real time. *The Lancet Infectious Diseases*, 20(5), 533-534.
464 doi:[https://doi.org/10.1016/S1473-3099\(20\)30120-1](https://doi.org/10.1016/S1473-3099(20)30120-1)
- 465 Dubios, M., Gilles, K. A., Hamilton, J. K., Rebers, P. A., & Smith, F. (1956). Colorimetric method for
466 determination of sugar and related substances. *Analytical Chemistry*, 28, 250-256.
467 doi:[10.1021/AC60111A017](https://doi.org/10.1021/AC60111A017)
- 468 Fujihara, M., & Nagumo, T. (1993). An influence of the structure of alginate on the chemotactic
469 activity of macrophages and the antitumor activity. *Carbohydrate Research*, 243(1), 211-216.
470 doi:[https://doi.org/10.1016/0008-6215\(93\)84094-M](https://doi.org/10.1016/0008-6215(93)84094-M)
- 471 Heyraud, A., Gey, C., Leonard, C., Rochas, C., Girond, S., & Kloareg, B. (1996). NMR spectroscopy
472 analysis of oligoguluronates and oligomannuronates prepared by acid or enzymatic hydrolysis
473 of homopolymeric blocks of alginic acid. Application to the determination of the substrate
474 specificity of *Haliotis tuberculata* alginate lyase. *Carbohydrate Research*, 289, 11-23.
475 doi:[https://doi.org/10.1016/0008-6215\(96\)00060-2](https://doi.org/10.1016/0008-6215(96)00060-2)
- 476 Kirchdoerfer, R. N., Cottrell, C. A., Wang, N., Pallesen, J., Yassine, H. M., Turner, H. L., et al. (2016).
477 Pre-fusion structure of a human coronavirus spike protein. *Nature*, 531(7592), 118-121.
478 doi:[10.1038/nature17200](https://doi.org/10.1038/nature17200)
- 479 Kuda, T., Kunii, T., Goto, H., Suzuki, T., & Yano, T. (2007). Varieties of antioxidant and antibacterial
480 properties of *Ecklonia stolonifera* and *Ecklonia kurome* products harvested and processed in
481 the Noto peninsula, Japan. *Food Chemistry*, 103(3), 900-905.
482 doi:<https://doi.org/10.1016/j.foodchem.2006.09.042>

- 483 Kumar, S., Maurya, V. K., Prasad, A. K., Bhatt, M. L. B., & Saxena, S. K. (2020). Structural,
484 glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and
485 SARS coronavirus (SARS-CoV). *VirusDisease*, *31*(1), 13-21.
486 doi:[10.1007/s13337-020-00571-5](https://doi.org/10.1007/s13337-020-00571-5)
- 487 Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., et al. (2020). Structure of the SARS-CoV-2 spike
488 receptor-binding domain bound to the ACE2 receptor. *Nature*, *581*(7807), 215-220.
489 doi:[10.1038/s41586-020-2180-5](https://doi.org/10.1038/s41586-020-2180-5)
- 490 Leung, P.-C. (2007). The efficacy of Chinese medicine for SARS: a review of Chinese publications
491 after the crisis. *The American Journal of Chinese Medicine*, *35*(04), 575-581.
492 doi:[10.1142/S0192415X07005077](https://doi.org/10.1142/S0192415X07005077)
- 493 Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., et al. (2003).
494 Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. *Nature*,
495 *426*(6965), 450-454. doi:[10.1038/nature02145](https://doi.org/10.1038/nature02145)
- 496 Li, Y., Qin, G., Cheng, C., Yuan, B., Huang, D., Cheng, S., et al. (2020). Purification, characterization
497 and anti-tumor activities of polysaccharides from *Ecklonia kurome* obtained by three different
498 extraction methods. *International Journal of Biological Macromolecules*, *150*, 1000-1010.
499 doi:<https://doi.org/10.1016/j.ijbiomac.2019.10.216>
- 500 Lin, C.-Z., Guan, H.-S., Li, H.-H., Yu, G.-L., Gu, C.-X., & Li, G.-Q. (2007). The influence of
501 molecular mass of sulfated propylene glycol ester of low-molecular-weight alginate on
502 anticoagulant activities. *European Polymer Journal*, *43*(7), 3009-3015.
503 doi:<https://doi.org/10.1016/j.eurpolymj.2007.04.015>
- 504 Lindahl, U., Couchman, J., Kimata, K., and Esko, J.D. (2015). *Proteoglycans and Sulfated*
505 *Glycosaminoglycans* (3rd ed.): Cold Spring Harbor Laboratory Press, Cold Spring Harbor
506 (NY), 207–221. doi: [10.1101/glycobiology.3e.017](https://doi.org/10.1101/glycobiology.3e.017)
- 507 Luo, C., Wu, W., Lou, S., Zhao, S., & Yang, K. (2020). Improving the in vivo bioavailability and in
508 vitro anti-inflammatory activity of tanshinone IIA by alginate solid dispersion. *Journal of*
509 *Drug Delivery Science and Technology*, *60*, 101966.
510 doi:<https://doi.org/10.1016/j.jddst.2020.101966>
- 511 Luo, H., Tang, Q.-L., Shang, Y.-X., Liang, S.-B., Yang, M., Robinson, N., & Liu, J.-P. (2020). Can
512 Chinese medicine be used for prevention of corona virus disease 2019 (COVID-19)? A
513 Review of Historical Classics, Research Evidence and Current Prevention Programs. *Chinese*
514 *Journal of Integrative Medicine*, *26*(4), 243-250. doi:[10.1007/s11655-020-3192-6](https://doi.org/10.1007/s11655-020-3192-6)
- 515 Mao, W., Li, B., Gu, Q., Fang, Y., & Xing, H. (2004). Preliminary studies on the chemical
516 characterization and antihyperlipidemic activity of polysaccharide from the brown *alga*
517 *Sargassum fusiforme*. *Hydrobiologia*, *512*(1), 263-266.
518 doi:[10.1023/B:HYDR.0000020335.46431.ad](https://doi.org/10.1023/B:HYDR.0000020335.46431.ad)
- 519 Milewska, A., Zarebski, M., Nowak, P., Stozek, K., Potempa, J., & Pyrc, K. (2014). Human
520 coronavirus NL63 utilizes heparan sulfate proteoglycans for attachment to target cells. *Journal*
521 *of Virology*, *88*(22), 13221. doi:[10.1128/JVI.02078-14](https://doi.org/10.1128/JVI.02078-14)
- 522 Shajahan, A., Supekar, N., Gleinich, A., & Azadi, P. (2020). Deducing the N- and O- glycosylation
523 profile of the spike protein of novel coronavirus SARS-CoV-2. *Glycobiology*, *30*(12),
524 981–988. <https://doi.org/10.1093/glycob/cwaa042>

- 525 Schürks, N., Wingender, J., Flemming, H. C., & Mayer, C. (2002). Monomer composition and
526 sequence of alginates from *Pseudomonas aeruginosa*. *International Journal of Biological*
527 *Macromolecules*, 30(2), 105-111. doi:[https://doi.org/10.1016/S0141-8130\(02\)00002-8](https://doi.org/10.1016/S0141-8130(02)00002-8)
- 528 Song, S., Peng, H., Wang, Q., Liu, Z., Dong, X., Wen, C., et al. (2020). Inhibitory activities of marine
529 sulfated polysaccharides against SARS-CoV-2. *Food & Function*, 11(9), 7415-7420.
530 doi:10.1039/D0FO02017F
- 531 Su, H.-X., Yao, S., Zhao, W.-F., Li, M.-J., Liu, J., Shang, W.-J., et al. (2020). Anti-SARS-CoV-2
532 activities in vitro of Shuanghuanglian preparations and bioactive ingredients. *Acta*
533 *Pharmacologica Sinica*, 41(9), 1167-1177. doi:[10.1038/s41401-020-0483-6](https://doi.org/10.1038/s41401-020-0483-6)
- 534 Taylor, R. L., & Conrad, H. E. (1972). Stoichiometric depolymerization of polyuronides and
535 glycosaminoglycuronans to monosaccharides following reduction of their
536 carbodiimide-activated carboxyl groups. *Biochemistry*, 11(8), 1383-1388.
537 doi:[10.1021/bi00758a009](https://doi.org/10.1021/bi00758a009)
- 538 Wen, C.-C., Shyur, L.-F., Jan, J.-T., Liang, P.-H., Kuo, C.-J., Arulselvan, P., et al. (2011). Traditional
539 Chinese medicine herbal extracts of *Cibotium barometz*, *Gentiana scabra*, *Dioscorea batatas*,
540 *Cassia tora*, and *Taxillus chinensis* inhibit SARS-CoV replication. *Journal of Iraditional and*
541 *Complementary Medicine*, 1(1), 41-50. doi:[10.1016/s2225-4110\(16\)30055-4](https://doi.org/10.1016/s2225-4110(16)30055-4)
- 542 Xue, X., Yang, H., Shen, W., Zhao, Q., Li, J., Yang, K., et al. (2007). Production of Authentic
543 SARS-CoV Mpro with Enhanced Activity: Application as a Novel Tag-cleavage
544 Endopeptidase for Protein Overproduction. *Journal of Molecular Biology*, 366(3), 965-975.
545 doi:<https://doi.org/10.1016/j.jmb.2006.11.073>
- 546 Yang, H., Xie, W., Xue, X., Yang, K., Ma, J., Liang, W., et al. (2005). Design of wide-spectrum
547 inhibitors targeting coronavirus main proteases. *PLOS Biology*, 3(10), e324.
548 doi:[10.1371/journal.pbio.0030324](https://doi.org/10.1371/journal.pbio.0030324)
- 549 Yang, H., Yang, M., Ding, Y., Liu, Y., Lou, Z., Zhou, Z., et al. (2003). The crystal structures of severe
550 acute respiratory syndrome virus main protease and its complex with an inhibitor. *Proceedings*
551 *of the National Academy of Sciences of the United States of AME*, 100(23), 13190.
552 doi:[10.1073/pnas.1835675100](https://doi.org/10.1073/pnas.1835675100)
- 553 Yin, W., Mao, C., Luan, X. D., Shen, D.-D., Shen, Q., Su, H., et al. (2020). Structural basis for
554 inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. *Science*,
555 368, eabc1560. doi:[10.1126/science.abc1560](https://doi.org/10.1126/science.abc1560)
- 556